Article Text

other Versions

PDF
Risk of breast cancer in male BRCA2 carriers
  1. D G R Evans1,
  2. I Susnerwala1,
  3. J Dawson1,
  4. E Woodward2,
  5. E R Maher2,
  6. F Lalloo1
  1. 1Genetic Medicine, Manchester Academic Health Science Centre, St. Mary's Hospital, Manchester, UK
  2. 2Department of Medical and Molecular Genetics, University of Birmingham School of Medicine, and West Midlands Regional Genetics Service, Birmingham, UK
  1. Correspondence to Professor D G R Evans, Consultant Clinical Geneticist, Genetic Medicine, Manchester Academic Health Science Centre, St. Mary's Hospital, Manchester M13 0JH, UK; gareth.evans{at}cmft.nhs.uk

Abstract

The risk of breast cancer for unaffected men who test positive for a BRCA2 mutation is based on very few retrospective studies. We have used both retrospective and prospective analysis in 321 families with pathogenic BRCA2 mutations. Three breast cancers occurred in male first-degree relatives after family ascertainment in 4140 years of follow-up suggesting a risk of breast cancer to 80 years of 8.9%. A second analysis excluding index cases identified 16 breast cancers in 905 first-degree male relatives on which Kaplan–Meier analysis was performed after assigning carrier status. This analysis confirmed that breast cancer risk in men was 7.1% (SE 5.2–8.6%) by age 70 years and 8.4% (SE 6.2–10.6%) by age 80 years.

Statistics from Altmetric.com

Footnotes

  • All authors contributed to the article.

  • Funding Other Funders: Genesis Appeal.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Central Manchester.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.